Kanika Sehgal, MBBS: The State of C Difficile Care

Video

There are several potential treatments on the horizon for C difficile infections.

The state of care for C difficile infections is improving rapidly by the day.

Fecal microbiota transplantation (FMT), live microbiome therapeutics (LMT), and new antibiotics have drastically led to improving care.

And a lot of the measures put in place during the COVID-19 pandemic has led to a drop in hospital-acquired infections.

With the state of care improving, new research suggests C difficile cases are not related to an increased risk of emotional distress for patients.

In an interview with HCPLive®, Kanika Sehgal, MBBS, Research Fellow at Mayo Clinic Rochester, explained the current state of C difficile care.

Sehgal recently presented data at 2022 Digestive Disease Week Annual Meeting in San Diego, on the psychological distress in patients at the time of symptom development for CDI.

In the study, the investigators examined adult patients with an index episode of CDI, no history of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).

All 8 patients developed abdominal pain that was present for at least 1 day per week and was related to change in bowel movement consistency and frequency.

Related Videos
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Brian Barnett, MD: Psychedelics Fitting into the SUDs Treatment Paradigm
Lenard A. Adler, MD: “Symptoms of ADHD Need to Go Back to Childhood”
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
3 Barriers to Improving Clozapine Use in Treatment-Resistant Schizophrenia
Evaluating MM120 for GAD with Daniel Karlin, MD, and Reid Robinson, MD, MBA
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
© 2024 MJH Life Sciences

All rights reserved.